CAS: 5355-48-6; β-Acetyldigoxin
该化合物是属于类卡登醇的复杂有机化合物,是血清凝胶,其特性为类卡登醇,该物质具有一种具有多羟基基的类固醇骨,特别是12和14个位置,有助于其生物活动.一种独特的甘醇结构的存在,由三个通过(14)债券连接的多氧-D-里博-赫索亚诺基体单元组成,增强了其溶性及其与生物系统的潜在互动.第一个糖组的4位置的乙基体组进一步改变其特性,有可能影响其药用动力学和生物活性.卡德-20(22)-奥利德因其对心脏功能的影响而闻名,经常用于治疗心脏病况.具体立体化学结构(3,5,12)对其生物活动至关重要,因为它决定了该化合物与细胞目标的相互作用.
- 英文名称β-Acetyldigoxin
- 中文名称β-乙酰地高辛
- IUPAC名称[(2R,3S,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl] acetate
- 其它别名ACETYLDIGOXIN, B-; BETA-ACETYLDIGOXIN; B-ACETYLDIGOXIN; 16’-acetyldigoxin; 4’’’-acetyldigoxin; acetate,beta-digoxi; acetyl-digoxin-beta; digoridb
- CAS编号5355-48-6
- MFCD编号:MFCD00242932
- EINECS号:226-337-5
- FDA UNII编号:P7K44M64CW
- 分子式:C43H66O15分子量:822.98
- 产品CID: 1519430
- 产品分类生物化工 → 糖类化合物 → 寡糖
物理性质
MSDS等安全信息
- GHS象形图
- GHS符号GHS06;
注释: Skull and crossbones - 危险类别急性毒性 类别2(吸入)
急性毒性 类别2(经口)
急性毒性 类别1(经口)
皮肤腐蚀 类别1A - 警示词Danger(危险)
- 危险描述H330 |吸入致命.
H300 |吞咽致命.
H314 |造成严重皮肤灼伤和眼损伤. - 防范说明P260-P301+P330+P331+P310-P304+P340+P310-P403+P233
- 危险等级6.1(a)
- UN编号3249
- 包装等级II
- 安全声明H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- WGK Germany3
欧盟法规
ECHA物质C&L通报REACH预注册上下游产品
CAS号75-36-5 乙酰氯 | CAS号20830-75-5 地高辛 | CAS号17575-22-3 毛花苷C | CAS号5511-98-8 地高辛杂质I | CAS号20830-75-5 地高辛 | CAS号1672-46-4 地黄苷元合成工艺路线路线简述
📜毛花苷c置于enzyme-Substance From Digitalis Lanata体系中,化学反应生成 β-乙酰地高辛
参考文献:乙酰数字毒素,乙酰基毒素和乙酰基地高辛(5. Mitteilungüberherzglucoside)
标题:乙酰数字毒素,乙酰基毒素和乙酰基地高辛(5. Mitteilungüberherzglucoside)
摘要:
DOI:10.1002/hlca.19340170169
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2905143000-叔丁醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:WO-0112817-A1
优先权日:1999-08-12
标题:Evolution and use of enzymes for combinathorial and medicinal chemistry
发明人：KREBBER CLAUS; DAVIS S CHRISTOPHER; DELCARDAYRE STEPHEN; SELIFONOV SERGEY A; HOWARD RUSSELL
权利人:MAXYGEN INC; LIU LU; KREBBER CLAUS; DAVIS S CHRISTOPHER; DELCARDAYRE STEPHEN; SELIFONOV SERGEY A; HOWARD RUSSELL
摘要:This invention provides libraries of recombinant derivatizing enzymes that are useful for biocatalytic synthesis of derivatives oforganic molecules, including lead compounds for pharmaceutical use. The recombinant derivatizing enzymes catalyze reactions such as modification or replacement of functional groups on the organicmolecules, or addition of chemical moieties onto preexisting functional groups. The use of recombinant enzyme libraries enables one to obtain enzymes that catalyze the formation of organic molecule derivatives that could not otherwise be made using only naturally occurring enzymes.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
摘要:Intensive Care Medicine., 4(199), 1978 []
摘要:Arzneimittel-Forschung. Drug Research., 19(687), 1969 []
摘要:Arzneimittel-Forschung. Drug Research., 21(225), 1971
摘要:Arzneimittel-Forschung. Drug Research., 15(483), 1965 []
摘要:Arzneimittel-Forschung. Drug Research., 15(481), 1965 []
📝 需求与反馈
尽可能描述清楚需求与问题信息
